Tumour SNPs Associated with Immune-Related Hepatitis in Patients with Melanoma Receiving Immune Checkpoint Inhibitors
| dc.contributor.author | Rodríguez Piñas, José María | |
| dc.contributor.author | Romero Lorca, Alicia | |
| dc.contributor.author | Gaibar Alonso, María | |
| dc.contributor.author | Novillo Villajos, Apolonia | |
| dc.contributor.author | Rubio Alonso, Margarita | |
| dc.contributor.author | Malón, Diego | |
| dc.contributor.author | Antón Pascual, Beatriz | |
| dc.contributor.author | Camacho Castañeda, Francisca Inmaculada | |
| dc.contributor.author | Cavanagh, Mercedes | |
| dc.contributor.author | Fernández Santander, Ana | |
| dc.contributor.author | Et. al. | |
| dc.date.accessioned | 2026-06-10T08:18:36Z | |
| dc.date.available | 2026-06-10T08:18:36Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | Immune checkpoint inhibitors (ICIs) have significantly improved survival rates for patients with metastatic melanoma. However, these treatments can lead to immune-related adverse events (irAEs), including hepatitis. This exploratory study sought to identify tumour single-nucleotide polymorphisms (SNPs) associated with the risk of ICI-induced hepatitis in melanoma patients. | en |
| dc.description.filiation | UEM | spa |
| dc.description.impact | 3.9 Q2 JCR 2024 | |
| dc.description.impact | 1.165 Q1 SJR 2025 | |
| dc.description.impact | No data IDR 2024 | |
| dc.description.sponsorship | Grant 2022/UEM19 | |
| dc.identifier.citation | Rodríguez-Piñas, J. M., Romero-Lorca, A., Gaibar, M., Novillo, A., Rubio, M., Malón, D., Antón-Pascual, B., Camacho, F. I., Cavanagh, M., Luján, D. R., Martín, A. M., Khedaoui, R., Moreno, D., Pinedo, F., Boiza, M., García-Adrián, S., Gómez, P., Marrupe, D., & Fernández-Santander, A. (2025). Tumour snps associated with immune-related hepatitis in patients with melanoma receiving immune checkpoint inhibitors. Biomedicines, 13(10), 2351. https://doi.org/10.3390/biomedicines13102351 | |
| dc.identifier.doi | 10.3390/biomedicines13102351 | |
| dc.identifier.issn | 2227-9059 | |
| dc.identifier.uri | https://hdl.handle.net/11268/17154 | |
| dc.language.iso | eng | |
| dc.peerreviewed | Si | |
| dc.relation.publisherversion | https://doi.org/10.3390/biomedicines13102351 | |
| dc.rights | Attribution 4.0 International | en |
| dc.rights.accessRights | open access | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject.other | Medicina | |
| dc.subject.other | Melanoma | |
| dc.subject.other | Biomarcadores | |
| dc.subject.other | Hepatitis | |
| dc.subject.sdg | Goal 3: Ensure healthy lives and promote well-being for all at all ages | |
| dc.subject.unesco | Cáncer | |
| dc.subject.unesco | Patología | |
| dc.subject.unesco | Inmunología | |
| dc.title | Tumour SNPs Associated with Immune-Related Hepatitis in Patients with Melanoma Receiving Immune Checkpoint Inhibitors | en |
| dc.type | journal article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 6df66eed-0c97-49a7-87e4-7052fb851239 | |
| relation.isAuthorOfPublication | d6fe9d38-0315-4e3c-974d-4b4a568ba81e | |
| relation.isAuthorOfPublication | 4b02f8da-816e-471d-b72b-000a5a37e0da | |
| relation.isAuthorOfPublication | 0413b5c5-4ebf-4116-b5d7-829f891a6e9c | |
| relation.isAuthorOfPublication | a0434fe0-b8a5-4674-a3f7-4a8f91004997 | |
| relation.isAuthorOfPublication | 8f0ff816-e791-403f-901d-e479575cf9e8 | |
| relation.isAuthorOfPublication.latestForDiscovery | 6df66eed-0c97-49a7-87e4-7052fb851239 |
Files
Original bundle
1 - 1 of 1

